TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1363221
Drug: F2/E2 group
Approvals — FDA: no, EMA: no, PMDA: no
Description: F2/E2 group (fentanyl 2 micrograms.kg‐1 and esmolol 2 mg.kg‐1)
Study: 1363221
Drug: E2 group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2 group (esmolol 2 mg.kg‐1)
Study: 30804464
Drug: Chlorthalidone-based stepped
Normalized name: Chlorthalidone
DrugBank: Chlorthalidone (DB00310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone-based stepped care therapy
Study: 30003628
Drug: Norwegian psychomotor
Normalized name: Norwegian Angelica
DrugBank: Angelica archangelica root (DB14283)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norwegian psychomotor physiotherapy (NPMP) once weekly for 6 months
Study: 23357150
Drug: Weekly lipid
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly lipid apheresis by cascade plasma filtration (CPF) plus atorvastatin
Study: 23357150
Drug: Atorvastatin alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin alone (control group)
Study: 23357150
Drug: Weekly lipid
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly lipid apheresis by cascade plasma filtration (CPF)
Study: 19874992
Drug: High-dose modified-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose modified-release nicotinic acid (2 g daily)
Study: 18210887
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment group (hepatectomy plus radiofrequency ablation and 125I implantation)
Study: 14648180
Drug: Bromocriptin (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptin (7.5 mg) combined with clomiphene citrate (150 mg on days 5-9)
Study: 14648180
Drug: Placebo combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo combined with clomiphene citrate (150 mg on days 5-9)
Study: 14648180
Drug: Bromocriptin (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptin (7.5 mg)
Study: 8165811
Drug: Cisapride 10
Normalized name: cisapride 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride 10 mg t.i.d. orally for 3 months in addition to oral litholysis (OLL) with ursodeoxycholic acid 500 mg/day and chenodeoxycholic acid 500 mg/day
Study: 8165811
Drug: Oral litholysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral litholysis (OLL) only
Study: 28177671
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg daily for 7 days
Study: 23286756
Drug: α‐tocopherol supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: α‐tocopherol supplementation (50 mg/day)
Study: 23286756
Drug: β‐carotene supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: β‐carotene supplementation (20 mg/day)
Study: 18421801
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg s.c. scopolamine
Study: 18421801
Drug: 0.4 mg
Normalized name: biotin 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg s.c. scopolamine
Study: 18421801
Drug: 0.6 mg
Normalized name: thymol 0.6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 mg s.c. scopolamine
Study: 12679702
Drug: Universal nevirapine
Normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Universal nevirapine (NVP) therapy
Study: 12679702
Drug: Targeted nevirapine
Normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Targeted nevirapine (NVP) therapy
Study: 10857891
Drug: Standard antiemetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antiemetic prophylaxis during cisplatin chemotherapy
Study: 7479228
Drug: i.v. injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. injection of heparin
Study: 27383814
Drug: Antibiotic Prophylaxis
Normalized name: STONE PROPHYLAXIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic Prophylaxis (AP+)
Study: 24158898
Drug: 10-day sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-day sequential regimen (40 mg of pantoprazole, 1 g of amoxicillin for the first 5 days, followed by 40 mg of pantoprazole, 500 mg of clarithromycin, and 500 mg of tinidazole for the remaining 5 days)
Study: 24158898
Drug: Standard 14-day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard 14-day therapy (40 mg of pantoprazole, 500 mg of clarithromycin, and 1 g of amoxicillin, each administered twice daily)
Study: 24158898
Drug: Standard 14-day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard 14-day therapy
Study: 21424566
Drug: Conventional bowel
Normalized name: ascorbic acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional bowel preparation (full cathartic dose and oral contrast medium for 3 days prior to study)
Study: 21424566
Drug: Reduced bowel
Normalized name: ascorbic acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced bowel preparation (oral contrast medium administered only on the day of investigation)
Study: 14644714
Drug: Daily disposable
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily disposable hydrogels
Study: 11004031
Drug: Perflubron emulsion
Normalized name: PERFLUBRON
DrugBank: Perflubron (DB05791)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Perflubron emulsion IV (1.2 g PFC/kg)
Study: 11004031
Drug: Perflubron emulsion
Normalized name: PERFLUBRON
DrugBank: Perflubron (DB05791)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Perflubron emulsion IV (1.8 g PFC/kg)
Study: 11004031
Drug: Saline (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (3 mL/kg) control
Study: 8400072
Drug: Pharmacist-assisted dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist-assisted dosing (Group 2)
Study: 8400072
Drug: Pharmacist-directed dosing
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist-directed dosing (Group 3)
Study: 8400072
Drug: Usual physician‐directed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual physician‐directed dosing (Group 1)
Study: 3536490
Drug: Labetalol at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labetalol at a dose of 0.8 mg kg‐1 (Group II)
Study: 29537453
Drug: Topical Tavaborole
Normalized name: tavaborole Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Tavaborole
Study: 22305462
Drug: Aspirin (81‐324
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (81‐324 mg per day)
Study: 15781736
Drug: Nesiritide (FDA-approved
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nesiritide (FDA-approved doses < or =0.03 microg x kg(‐1) x min(‐1))
Study: 15781736
Drug: Nesiritide (any
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nesiritide (any dose up to 0.06 microg x kg(‐1) x min(‐1))
Study: 15781736
Drug: Low-dose nesiritide
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose nesiritide (< or =0.015 microg x kg(‐1) x min(‐1))
Study: 15781736
Drug: Nesiritide (FDA-approved
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nesiritide (FDA-approved doses)
Study: 15781736
Drug: Any control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any control therapy (including non-inotrope- and inotrope-based therapies)
Study: 1800105
Drug: Four units
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four units of alcohol (95 ml of 40% spirit)
Study: 6479183
Drug: Dihydralazine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydralazine (25 mg i.v.)
Study: 6479183
Drug: Dihydralazine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydralazine (100 mg oral)
Study: 6479183
Drug: Dihydralazine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydralazine (20 mg day‐1 oral)
Study: 31485809
Drug: Pre-incisional nefopam
Normalized name: nefopam
DrugBank: Nefopam (DB12293)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-incisional nefopam (20 mg before skin incision)
Study: 31485809
Drug: Post-incisional nefopam
Normalized name: nefopam
DrugBank: Nefopam (DB12293)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-incisional nefopam (20 mg at 1 h after incision)
Study: 29419934
Drug: Nafamostat mesilate
Normalized name: mesylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nafamostat mesilate (NM) at 0.5 mg/kg/h during IHD for 5 hours
Study: 29419934
Drug: Nafamostat mesilate
Normalized name: mesylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nafamostat mesilate (NM) at 0.25 mg/kg/h during IHD
Study: 29419934
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (UFH) during IHD
Study: 24309219
Drug: Oral ibuprofen,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ibuprofen, 800 mg given 60-90 min preprocedure
Study: 24309219
Drug: Intramuscular ketorolac,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular ketorolac, 60 mg given 30-60 min preprocedure
Study: 19765954
Drug: L-glutamine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-glutamine (0.5 g kg(‐1) d(‐1))
Study: 18380208
Drug: Hydrocortisone butyrate
Normalized name: Hydrocortisone Butyrate
DrugBank: Hydrocortisone butyrate (DB14540)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrocortisone butyrate 0.1% lotion
Study: 16079640
Drug: Pravastatin, 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin, 40 mg daily
Study: 7670782
Drug: GTN patches
Normalized name: GTN
Approvals — FDA: no, EMA: no, PMDA: no
Description: GTN patches (0.2 mg/h)
Study: 3103163
Drug: Aniracetam 1
Normalized name: aniracetam
DrugBank: Aniracetam (DB04599)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aniracetam 1 g daily for 3 months
Study: 28587649
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural therapy (CBT) plus standardised medical care (SMC)
Study: 23522532
Drug: Buccal infiltration
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buccal infiltration of 1.8 mL 4% articaine hydrochloride with 1:100,000 adrenaline at the canine and first molar
Study: 23522532
Drug: Buccal infiltration
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buccal infiltration at the second molar
Study: 23522532
Drug: Injections at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injections at adjacent sites (canine and first molar)
Study: 23522532
Drug: Injections at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injections at different sites of the mandible
Study: 11413894
Drug: Antihypertensive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive therapy (specific drugs not mentioned)
Study: 2725119
Drug: Nicotine dose
Normalized name: nicotine Metered Dose Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine dose adapted to daily cigarette consumption (n = 51)
Study: 2725119
Drug: Standardized nicotine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized nicotine dose (n = 49)
Study: 29151484
Drug: Glucosamine (3000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucosamine (3000 mg/day for 4 weeks)
Study: 18022173
Drug: Folate (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Folate (0.5 mg/day)
Study: 11840583
Drug: oral midazolam,
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral midazolam, 0.2 mg/kg as anesthetic premedication
Study: 11840583
Drug: saline (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: saline (oral normal saline as premedication)
Study: 9512243
Drug: Earle's balanced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Earle's balanced salt solution (control)
Study: 2847567
Drug: 0.75 ml/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75 ml/kg of ethanol
Study: 2847567
Drug: 1.1 ml/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.1 ml/kg of ethanol
Study: 29405274
Drug: Gemcitabine chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine chemotherapy (1000 mg/m2, administered on days 1, 8, and 15 every 4 weeks for six cycles)
Study: 29405274
Drug: Gemcitabine chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine chemotherapy
Study: 25062592
Drug: Family-focused therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family-focused therapy for individuals at clinical high risk (FFT-CHR), 18 sessions over 6 months
Study: 25062592
Drug: Family-focused therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family-focused therapy for individuals at clinical high risk (FFT-CHR)
Study: 20547106
Drug: Adjunctive levetiracetam
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Adjunctive levetiracetam (LEV) 20‐60mg/kg/day
Study: 18993165
Drug: L-Carnitine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-Carnitine (2 g/day)
Study: 16076146
Drug: 250 g
Normalized name: WORMWOOD OIL 100 g in 250 g TOPICAL GEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 g raw purple carrots (463 micromol of anthocyanins: 400 micromol acylated, 63 micromol nonacylated)
Study: 16076146
Drug: 250 g
Normalized name: WORMWOOD OIL 100 g in 250 g TOPICAL GEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 g cooked purple carrots (357 micromol of anthocyanins: 308.5 micromol acylated, 48.5 micromol nonacylated)
Study: 16076146
Drug: 500 g
Normalized name: PRAZIQUANTEL 500 g in 500 g POWDER
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 g cooked purple carrots (714 micromol of anthocyanins: 617 micromol acylated, 97 micromol nonacylated)
Study: 7432323
Drug: High doses
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High doses of immunoglobulins (Ig)
Study: 9665110
Drug: Beta-carotene (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-carotene (50 mg on alternate days for an average of 12 years)
Study: 2503432
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (ISDN) 20 mg or more, oral administration three or four times a day
Study: 2503432
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (ISDN) during maintenance therapy
Study: 22009509
Drug: Mifepristone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone (200 mg) followed by buccal misoprostol (800 µg)
Study: 22009509
Drug: Buccal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Buccal misoprostol (800 µg only)
Study: 7820333
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg/day for 7 days
Study: 7820333
Drug: Fluconazole 100
Normalized name: fluconazole 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole 100 mg after omeprazole treatment
Study: 7820333
Drug: Fluconazole 100
Normalized name: fluconazole 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole 100 mg before omeprazole treatment
Study: 28212163
Drug: Concurrent multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent multiple organ dysfunction syndrome (MODS)
Study: 25913848
Drug: High MUFA
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High MUFA shake (95 g)
Study: 25913848
Drug: High SFA
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High SFA shake (95 g)
Study: 23680708
Drug: Standard triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard triple therapy with concomitant probiotic (Bifidus infantis)
Study: 23680708
Drug: Standard triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard triple therapy with pre-treatment of probiotic (Bifidus infantis for 2 weeks)
Study: 23680708
Drug: Sequential therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential therapy with concomitant probiotic (Bifidus infantis)
Study: 23680708
Drug: Traditional standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional standard triple therapy (control group)
Study: 21305611
Drug: Nicotine-containing lozenge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine-containing lozenge (NL)
Study: 17162243
Drug: Serum insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Serum insulin
Study: 31818152
Drug: Acetaminophen (APAP),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (APAP), 4 grams daily for two weeks
Study: 31818152
Drug: Acetaminophen (APAP)
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (APAP) with 20 mL propylene glycol (PG), 4 grams daily for two weeks
Study: 23343395
Drug: HIV vaccine
Normalized name: AAV-2 HIV Vaccine
DrugBank: TGAAC09 (DB06363)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV vaccine trial (RV 144 prime-boost)
Study: 9411464
Drug: Pharmacological treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological treatment with antidepressants
Study: 9411464
Drug: Psychological and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychological and pharmacological treatments
Study: 8160789
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of endothelin-1 (ET-1) at a rate of 1 pmol.min-1.kg-1 for 60 min
Study: 8160789
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of endothelin-1 (ET-1)
Study: 28987930
Drug: new drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: new drugs
Study: 28583653
Drug: Prospectively ECG‐triggered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prospectively ECG‐triggered high‐pitch CCTA at 70 kVp with 30mL contrast agent (protocol A)
Study: 28583653
Drug: Prospectively ECG‐triggered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prospectively ECG‐triggered sequential scanning at 120 kVp and 60mL contrast medium (protocol B)
Study: 24059131
Drug: Timely ovulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timely ovulation induction with clomiphene citrate tablets at the first menstrual cycle post-operation
Study: 24059131
Drug: Expectant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Expectant treatment only
Study: 21403575
Drug: Amoxicillin 1
Normalized name: amoxicillin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin 1 g orally 1 h before surgery
Study: 21403575
Drug: Metronidazole 800
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metronidazole 800 mg orally 1 h before surgery
Study: 10740162
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium (15 g over a 48-hour period)
Study: 10740162
Drug: Placebo (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (intravenous dextrose solution)
Study: 1313549
Drug: Ganciclovir (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ganciclovir (5 mg/kg every 12 hours for 14 days, then 6 mg/kg daily for 5 days per week until day 28)
Study: 27514617
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg clopidogrel
Study: 18765393
Drug: 900 mg
Normalized name: diosmin 900 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900 mg clopidogrel
Study: 18765393
Drug: 900 mg
Normalized name: diosmin 900 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900 mg clopidogrel (after initial loading)
Study: 7676980
Drug: 3 ml/sec
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 ml/sec uniphasic
Study: 7676980
Drug: 2 ml/sec
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 ml/sec uniphasic
Study: 7676980
Drug: 3 ml/sec
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 ml/sec biphasic
Study: 2161058
Drug: Pipecuronium bromide
Normalized name: pipecuronium bromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pipecuronium bromide (PPB) 0.01 mg.kg-1
Study: 2161058
Drug: Pipecuronium bromide
Normalized name: pipecuronium bromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pipecuronium bromide (PPB) 0.05 mg.kg-1 or 0.1 mg.kg-1
Study: 2161058
Drug: Pancuronium bromide
Normalized name: Pancuronium Bromide
DrugBank: Pancuronium (DB01337)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pancuronium bromide (PCB) 0.01 mg.kg-1
Study: 30630161
Drug: Intranasal oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal oxytocin (40 IU, n = 29)
Study: 23168378
Drug: New magnetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: New magnetic suspension system
Study: 16092057
Drug: Micronized fenofibrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronized fenofibrate (200 mg/d)
Study: 16092057
Drug: Atorvastatin and
Normalized name: atorvastatin and ezetimibe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin and micronized fenofibrate (combination)
Study: 12893114
Drug: Biomedical, psychosocial,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biomedical, psychosocial, and combined medical-psychosocial approaches to treatment
Study: 10553851
Drug: Remifentanil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil infusion at 0.125 microg x kg(‐1) x min(‐1) (Group 2)
Study: 10553851
Drug: Remifentanil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil infusion at 0.0625 microg x kg(‐1) x min(‐1) (Group 1)
Study: 10553851
Drug: Remifentanil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil infusion at 0.250 microg x kg(‐1) x min(‐1) (Group 3)
Study: 15278644
Drug: Intravenous aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous aspirin DL‐lysine 900 mg (equivalent to aspirin 495 mg)
Study: 6689676
Drug: Nifedipine 40
Normalized name: nifedipine 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 40 mg
Study: 19364966
Drug: Trastuzumab (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab (1 year after chemotherapy)
Study: 17331237
Drug: Collaborative care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collaborative care approach including Problem Solving Treatment and antidepressant treatment algorithm
Study: 15372171
Drug: Hyoid suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyoid suspension surgery
Study: 20525211
Drug: A allele
Normalized name: Human leucocyte antigen A allele
Approvals — FDA: no, EMA: no, PMDA: no
Description: A allele of the angiotensin II type 1 receptor
Study: 12574224
Drug: Hyperthyroid patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperthyroid patients before treatment